Bausch + Lomb and Celldex have independently reported phase 2 flops. While Celldex ended work in the indication in response to the setback, Bausch + Lomb noted numerical improvements and exploratory analyses to make the case for talks about entering phase 3.
Celldex’s clinical trial compared the anti-KIT antibody barzolvolimab to placebo in people with moderate-to-severe atopic dermatitis. At Week 16, the percentage change from baseline in the weekly average of the daily peak itch score was statistically no better on barzolvolimab than on placebo, meaning the study missed its primary endpoint. The trial also missed key secondary endpoints.
The biotech reported some undefined benefit from the study drug, but the improvements fell short of its bar for continued development. Celldex is stopping development in atopic dermatitis while continuing to work toward a planned filing for approval in chronic spontaneous urticaria (CSU) next year.
TD Cowen analysts lowered expectations for the atopic dermatitis readout after barzolvolimab failed a phase 2 prurigo nodularis trial in July. Celldex targeted the two indications based on evidence that mast cells, which barzolvolimab depletes, drive itching in both skin diseases.
Back-to-back midphase failures have dealt a blow to that hypothesis, but barzolvolimab appears active in other settings. The biotech reported phase 3 wins in CSU in September, although its stock dropped amid concerns about anaphylaxis.
Bausch + Lomb’s own midphase failure affected BL1332, a topical TRPV1 antagonist that the company tested in patients with pain following photorefractive keratectomy surgery. Neither dose performed significantly better than the vehicle control on the sum of pain intensity differences (SPID) over 24 hours, the primary endpoint. But BL1332 performed numerically better on primary, secondary and exploratory assessments.
“What stands out from this study is the consistency of the findings,” Yehia Hashad, M.D., chief medical officer at Bausch + Lomb, said in a statement. “Both dose groups showed numerically greater pain relief than vehicle across all the pain measures we evaluated, more patients achieved complete pain relief following surgery and we observed evidence of faster corneal healing.”
The consistency of the efficacy trends, coupled with an acceptable safety profile, led Bausch + Lomb to lay out plans to discuss the data with the FDA. While SPID is the FDA’s recommended primary endpoint, Bausch + Lomb will discuss other measures with the agency.
“Our goal is to demonstrate what’s meaningful to patients, and certainly, being pain-free is meaningful,” Mayssa Attar, Ph.D., senior vice president of R&D at Bausch + Lomb, said on a call with investors to discuss the data. “So, that’s something we would like to explore with the FDA, recognizing each asset and drug will have its own attributes that need to be demonstrated as clinically meaningful to patients.”
The company will need about six months to fully analyze the data and prepare briefing packages, Hashad said on the call. Hashad declined to say when Bausch + Lomb would reach a go/no-go decision on the program, telling analysts that it will depend on talks with regulatory authorities.